1. Home
  2. REPL vs ANSC Comparison

REPL vs ANSC Comparison

Compare REPL & ANSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • ANSC
  • Stock Information
  • Founded
  • REPL 2015
  • ANSC 2021
  • Country
  • REPL United States
  • ANSC United States
  • Employees
  • REPL N/A
  • ANSC N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • ANSC
  • Sector
  • REPL Health Care
  • ANSC
  • Exchange
  • REPL Nasdaq
  • ANSC Nasdaq
  • Market Cap
  • REPL 547.0M
  • ANSC 466.6M
  • IPO Year
  • REPL 2018
  • ANSC 2023
  • Fundamental
  • Price
  • REPL $5.80
  • ANSC $10.94
  • Analyst Decision
  • REPL Hold
  • ANSC
  • Analyst Count
  • REPL 9
  • ANSC 0
  • Target Price
  • REPL $7.00
  • ANSC N/A
  • AVG Volume (30 Days)
  • REPL 2.5M
  • ANSC 13.9K
  • Earning Date
  • REPL 11-11-2025
  • ANSC 01-01-0001
  • Dividend Yield
  • REPL N/A
  • ANSC N/A
  • EPS Growth
  • REPL N/A
  • ANSC N/A
  • EPS
  • REPL N/A
  • ANSC 0.14
  • Revenue
  • REPL N/A
  • ANSC N/A
  • Revenue This Year
  • REPL N/A
  • ANSC N/A
  • Revenue Next Year
  • REPL $408.25
  • ANSC N/A
  • P/E Ratio
  • REPL N/A
  • ANSC $80.15
  • Revenue Growth
  • REPL N/A
  • ANSC N/A
  • 52 Week Low
  • REPL $2.68
  • ANSC $10.32
  • 52 Week High
  • REPL $17.00
  • ANSC $10.94
  • Technical
  • Relative Strength Index (RSI)
  • REPL 47.90
  • ANSC 66.77
  • Support Level
  • REPL $5.74
  • ANSC $10.90
  • Resistance Level
  • REPL $6.15
  • ANSC $10.87
  • Average True Range (ATR)
  • REPL 0.35
  • ANSC 0.01
  • MACD
  • REPL 0.12
  • ANSC 0.00
  • Stochastic Oscillator
  • REPL 41.03
  • ANSC 100.00

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About ANSC Agriculture & Natural Solutions Acquisition Corporation

Agriculture & Natural Solutions Acquisition Corp is a blank check company.

Share on Social Networks: